Flurizan Shows Continued Benefit In Alzheimer's Disease

Myriad Genetics, Inc. (MYGN charts news Powerrating) said Sunday that data from its Phase 2 follow-on study of Flurizan in patients with mild Alzheimer's disease suggest that the participants on 800 mg BID of Flurizan continued to demonstrate increasing benefit through month 21 in the area of cognition and memory loss. The data is being presented at the 19th annual meeting of the AAGP.
The data suggest that the benefit of Flurizan on the measures of Alzheimer's disease increases in terms of both effect size and significance, the longer patients remain on Flurizan.
Flurizan is the first in a new class of drug candidates known as Selective of Amyloid beta-42 - the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. Based on the positive Phase 2 results, Myriad is enrolling patients with mild Alzheimer's disease for a Phase 3 trial.

Stolen memoriesBrisbane Courier Mail - Queensland, Australia... is big business - the drug company that backs research which leads to a big dent in Alzheimer's will become a powerful beast. The beta-amyloid hypothesis is in ...